Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice.
about
Improving the predictive value of interventional animal models dataGRK5 Deficiency Leads to Selective Basal Forebrain Cholinergic Neuronal Vulnerability.Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.Specific serotonergic denervation affects tau pathology and cognition without altering senile plaques deposition in APP/PS1 mice.Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models.IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.Barriers to developing a valid rodent model of Alzheimer's disease: from behavioral analysis to etiological mechanismsIncreased Spontaneous Central Bleeding and Cognition Impairment in APP/PS1 Mice with Poorly Controlled Diabetes Mellitus.BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease.Long-Term Mangiferin Extract Treatment Improves Central Pathology and Cognitive Deficits in APP/PS1 Mice.Loss of Endothelial Nitric Oxide Synthase Promotes p25 Generation and Tau Phosphorylation in a Murine Model of Alzheimer's Disease.Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimer's Disease.Effects of brain-derived neurotrophic factor-pretreated neuron stem cell transplantation on Alzheimer's disease model mice.Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.Aerosol Delivery of Curcumin Reduced Amyloid-β Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer's Disease.Cholinergic Basal Forebrain Lesion Decreases Neurotrophin Signaling without Affecting Tau Hyperphosphorylation in Genetically Susceptible Mice.Acute Down-regulation of BDNF Signaling Does Not Replicate Exacerbated Amyloid-β Levels and Cognitive Impairment Induced by Cholinergic Basal Forebrain Lesion.Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine.The cholinergic system in the pathophysiology and treatment of Alzheimer's disease
P2860
Q27026822-D4A62AAA-F5D2-4708-92A8-A82D2FF8AB77Q33363144-50B4A1BB-A379-4C0D-89A8-4F39CBF470E0Q34459137-F71B38FC-47D1-4EFB-B286-5DDF8B62D22DQ35053378-36F144F4-3A35-4BEC-8B38-B6F636775918Q35106896-D1A149F4-ED77-4F4E-88D9-3A8610FA90D0Q35147651-549824E5-B851-4A5F-87A7-B445C1F600C8Q35898532-937114C9-3A54-48D5-AC6C-E1F530A98601Q36772914-6E48C054-DFFF-4FE2-A067-67063FE528BCQ37353095-1CEA6E9A-9415-40BA-9262-318E85D9C900Q38839191-EFC049C5-03C4-4FF7-8288-68E92927E1A1Q39416237-B99F1399-9F5E-4EE7-A38A-2DE6C8C04589Q39767994-4C2E52B6-237D-4D91-9FA9-28943957B2D2Q39991497-3683C9BA-56BD-4F15-9348-D13CDB503E59Q47336486-0597DCFC-E335-43E4-B373-E4A8C0E8EC6FQ48447497-2E9B817E-5EB7-4851-8E02-618877A613BEQ48467687-7328EB21-510F-451C-AEFB-2DADA136C01DQ50531667-49D65B33-8E19-45B0-9B44-ACDCA2B7B867Q55399027-3807C782-4B89-48B4-A07B-26A96828767AQ57177786-4EEBD24E-AEAD-44E7-8D59-41963497A987
P2860
Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Rapid β-amyloid deposition and ...... c denervation in APP/PS1 mice.
@en
Rapid β-amyloid deposition and ...... c denervation in APP/PS1 mice.
@nl
type
label
Rapid β-amyloid deposition and ...... c denervation in APP/PS1 mice.
@en
Rapid β-amyloid deposition and ...... c denervation in APP/PS1 mice.
@nl
prefLabel
Rapid β-amyloid deposition and ...... c denervation in APP/PS1 mice.
@en
Rapid β-amyloid deposition and ...... c denervation in APP/PS1 mice.
@nl
P2093
P2860
P50
P1476
Rapid β-amyloid deposition and ...... c denervation in APP/PS1 mice.
@en
P2093
Brian J Bacskai
Diana Thyssen
Mar Pacheco-Herrero
P2860
P304
P356
10.1097/NEN.0B013E318288A8DD
P50
P577
2013-04-01T00:00:00Z